{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:53:00Z","timestamp":1789617180941,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cell division cycle 25 (CDC25) phosphatases serve as crucial regulators of cell cycle phase transitions and essential components of the checkpoint machinery involved in DNA damage response. Emerging evidence indicates the oncogenic potential of CDC25 family members across various cancers. However, comprehensive insights into the expression pattern and function of the CDC25 family in diverse cancers remain unexplored. In our study, we investigated CDC25 family using multiple databases, including gene expression levels, molecular signatures, diagnosis value, and prognostic value in pan-cancer. Furthermore, we focused on melanoma and systematically explored CDC25A expression and its clinical correlations. As a result, the expression of CDC25 family members is significantly abnormal in most cancers, correlating with poorer prognosis. CDC25 family members are differently regulated by DNA methylation and genetic alterations across various cancers. In addition, CDC25 family plays a critical role in the malignant progression of melanoma. Functional investigation reveals that CDC25A inhibition suppresses the proliferation of melanoma cells and sensitizes melanoma cells to chemotherapy and NK cell therapy. In conclusion, our study suggests that CDC25 family may serve as a significant biomarker for diagnosis and prognosis across multiple cancers, with CDC25A as a promising therapeutic target for melanoma.<\/jats:p>","DOI":"10.1038\/s41419-025-07598-w","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:16:17Z","timestamp":1744370177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CDC25A inhibition sensitizes melanoma cells to doxorubicin and NK cell therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Xinyue","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feichang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-6660","authenticated-orcid":false,"given":"Hongyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-2375","authenticated-orcid":false,"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5342-0637","authenticated-orcid":false,"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"7598_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029\u201330","journal-title":"Cancer"},{"key":"7598_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363","journal-title":"CA Cancer J Clin"},{"key":"7598_CR3","doi-asserted-by":"publisher","first-page":"e1942","DOI":"10.1002\/wnan.1942","volume":"16","author":"SS Rajan","year":"2024","unstructured":"Rajan SS, Chandran R, Abrahamse H. Overcoming challenges in cancer treatment: Nano-enabled photodynamic therapy as a viable solution. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16:e1942","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"7598_CR4","doi-asserted-by":"publisher","first-page":"216332","DOI":"10.1016\/j.canlet.2023.216332","volume":"570","author":"W Wang","year":"2023","unstructured":"Wang W, Li M, Wang L, Chen L, Goh BC. Curcumin in cancer therapy: exploring molecular mechanisms and overcoming clinical challenges. Cancer Lett. 2023;570:216332","journal-title":"Cancer Lett"},{"key":"7598_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2013.05.009","volume":"24","author":"M Saez-Ayala","year":"2013","unstructured":"Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, Fernandez-Perez MP, Chazarra S, Freter R, et al. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell. 2013;24:105\u201319","journal-title":"Cancer Cell"},{"key":"7598_CR6","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1158\/0008-5472.CAN-23-0485","volume":"83","author":"LP Ferretti","year":"2023","unstructured":"Ferretti LP, Bohi F, Leslie Pedrioli DM, Cheng PF, Ferrari E, Baumgaertner P, et al. Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma. Cancer Res. 2023;83:3974\u201388","journal-title":"Cancer Res"},{"key":"7598_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502","journal-title":"Lancet"},{"key":"7598_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","volume":"39","author":"EE Patton","year":"2021","unstructured":"Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, et al. Melanoma models for the next generation of therapies. Cancer Cell. 2021;39:610\u201331","journal-title":"Cancer Cell"},{"key":"7598_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32:30\u201344","journal-title":"Trends Cell Biol"},{"key":"7598_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346","journal-title":"Cancer Discov"},{"key":"7598_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4615-4253-7_10","volume":"4","author":"I Nilsson","year":"2000","unstructured":"Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res. 2000;4:107\u201314","journal-title":"Prog Cell Cycle Res"},{"key":"7598_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrc2169","volume":"7","author":"R Boutros","year":"2007","unstructured":"Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer. 2007;7:495\u2013507","journal-title":"Nat Rev Cancer"},{"key":"7598_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/187152012800617678","volume":"12","author":"T Shen","year":"2012","unstructured":"Shen T, Huang S. The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 2012;12:631\u20139","journal-title":"Anticancer Agents Med Chem"},{"key":"7598_CR14","doi-asserted-by":"publisher","first-page":"113984","DOI":"10.1016\/j.envpol.2020.113984","volume":"260","author":"B Wang","year":"2020","unstructured":"Wang B, Xu S, Lu X, Ma L, Gao L, Zhang SY, et al. Reactive oxygen species-mediated cellular genotoxic stress is involved in 1-nitropyrene-induced trophoblast cycle arrest and fetal growth restriction. Environ Pollut. 2020;260:113984","journal-title":"Environ Pollut"},{"key":"7598_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0960-9822(02)70769-0","volume":"6","author":"M Zornig","year":"1996","unstructured":"Zornig M, Evan GI. Cell cycle: on target with Myc. Curr Biol. 1996;6:1553\u20136","journal-title":"Curr Biol"},{"key":"7598_CR16","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1038\/sj.onc.1203908","volume":"19","author":"C Sandhu","year":"2000","unstructured":"Sandhu C, Donovan J, Bhattacharya N, Stampfer M, Worland P, Slingerland J. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Oncogene. 2000;19:5314\u201323","journal-title":"Oncogene"},{"key":"7598_CR17","doi-asserted-by":"publisher","first-page":"22896","DOI":"10.1002\/jcp.28852","volume":"234","author":"Y Shen","year":"2019","unstructured":"Shen Y, Pan X, Yang J. Gene regulation and prognostic indicators of lung squamous cell carcinoma: TCGA-derived miRNA\/mRNA sequencing and DNA methylation data. J Cell Physiol. 2019;234:22896\u2013910","journal-title":"J Cell Physiol"},{"key":"7598_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12967-021-03043-6","volume":"19","author":"X Ma","year":"2021","unstructured":"Ma X, Yang S, Jiang H, Wang Y, Xiang Z. Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma. J Transl Med. 2021;19:368","journal-title":"J Transl Med"},{"key":"7598_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0083-6729(04)68008-3","volume":"68","author":"SS Chua","year":"2004","unstructured":"Chua SS, Ma Z, Ngan E, Tsai SY. Cdc25B as a steroid receptor coactivator. Vitam Horm. 2004;68:231\u201356","journal-title":"Vitam Horm"},{"key":"7598_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/ncb994","volume":"5","author":"DV Bulavin","year":"2003","unstructured":"Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol. 2003;5:545\u201351","journal-title":"Nat Cell Biol"},{"key":"7598_CR21","doi-asserted-by":"publisher","first-page":"113041","DOI":"10.1016\/j.celrep.2023.113041","volume":"42","author":"N Xu","year":"2023","unstructured":"Xu N, Ren Y, Bao Y, Shen X, Kang J, Wang N, et al. PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C. Cell Rep. 2023;42:113041","journal-title":"Cell Rep"},{"key":"7598_CR22","doi-asserted-by":"publisher","first-page":"13089","DOI":"10.1080\/21655979.2022.2078940","volume":"13","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang L, Hu W, Tang L, Zhang P, Gao Y, et al. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma. Bioengineered. 2022;13:13089\u2013107","journal-title":"Bioengineered"},{"key":"7598_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13046-020-01588-w","volume":"39","author":"K Liu","year":"2020","unstructured":"Liu K, Zheng M, Zhao Q, Zhang K, Li Z, Fu F, et al. Different p53 genotypes regulating different phosphorylation sites and subcellular location of CDC25C associated with the formation of polyploid giant cancer cells. J Exp Clin Cancer Res. 2020;39:83","journal-title":"J Exp Clin Cancer Res"},{"key":"7598_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","volume":"141","author":"RW Jenkins","year":"2021","unstructured":"Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Investig Dermatol. 2021;141:23\u201331","journal-title":"J Investig Dermatol"},{"key":"7598_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022;21:559\u201377","journal-title":"Nat Rev Drug Discov"},{"key":"7598_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1126\/science.7667636","volume":"269","author":"K Galaktionov","year":"1995","unstructured":"Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, et al. CDC25 phosphatases as potential human oncogenes. Science. 1995;269:1575\u20137","journal-title":"Science"},{"key":"7598_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04342-y","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Zeng J, Li LJ, Xue M, He SL. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells. Cell Death Dis. 2021;12.1055","journal-title":"Cell Death Dis"},{"key":"7598_CR28","doi-asserted-by":"publisher","first-page":"102418","DOI":"10.1016\/j.redox.2022.102418","volume":"55","author":"P Guo","year":"2022","unstructured":"Guo P, Zu S, Han S, Yu W, Xue G, Lu X, et al. BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A. Redox Biol. 2022;55:102418","journal-title":"Redox Biol"},{"key":"7598_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1479-5876-8-81","volume":"8","author":"J Dong","year":"2010","unstructured":"Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010;8:81","journal-title":"J Transl Med"},{"key":"7598_CR30","first-page":"3043","volume":"60","author":"I Takemasa","year":"2000","unstructured":"Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 2000;60:3043\u201350","journal-title":"Cancer Res"},{"key":"7598_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484\u201392","journal-title":"Nat Rev Genet"},{"key":"7598_CR32","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","volume":"41","author":"EP Henske","year":"2023","unstructured":"Henske EP, Cheng L, Hakimi AA, Choueiri TK, Braun DA. Chromophobe renal cell carcinoma. Cancer Cell. 2023;41:1383\u20138","journal-title":"Cancer Cell"},{"key":"7598_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","volume":"31","author":"A Gonzalez","year":"2020","unstructured":"Gonzalez A, Hall MN, Lin SC, Hardie DG. AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31:472\u201392","journal-title":"Cell Metab"},{"key":"7598_CR34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.onc.1206121","volume":"22","author":"ES Ngan","year":"2003","unstructured":"Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 2003;22:734\u20139","journal-title":"Oncogene"},{"key":"7598_CR35","first-page":"4082","volume":"58","author":"W Wu","year":"1998","unstructured":"Wu W, Fan YH, Kemp BL, Walsh G, Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082\u20135","journal-title":"Cancer Res"},{"key":"7598_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100564","volume":"296","author":"YC Chen","year":"2021","unstructured":"Chen YC, Hsieh HH, Chang HC, Wang HC, Lin WJ, Lin JJ. CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner. J Biol Chem. 2021;296.100564","journal-title":"J Biol Chem"},{"key":"7598_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101791","volume":"38","author":"Z Guo","year":"2023","unstructured":"Guo Z, Guo L. YAP\/TEAD-induced PRIM1 contributes to the progression and poor prognosis of gastric carcinoma. Transl Oncol. 2023;38.101791","journal-title":"Transl Oncol"},{"key":"7598_CR38","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-15-3278","volume":"76","author":"M Klutstein","year":"2016","unstructured":"Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76:3446\u201350","journal-title":"Cancer Res"},{"key":"7598_CR39","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37:1012\u201327","journal-title":"Trends Genet"},{"key":"7598_CR40","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/s41467-020-17667-7","volume":"11","author":"X Gao","year":"2020","unstructured":"Gao X, Wang Q, Wang Y, Liu J, Liu S, Liu J, et al. The REGgamma inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells. Nat Commun. 2020;11:3904","journal-title":"Nat Commun"},{"key":"7598_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.freeradbiomed.2021.08.242","volume":"175","author":"J Xu","year":"2021","unstructured":"Xu J, Li D, Lu Y, Zheng TY. Abeta monomers protect lens epithelial cells against oxidative stress by upregulating CDC25B. Free Radic Biol Med. 2021;175:161\u201370","journal-title":"Free Radic Biol Med"},{"key":"7598_CR42","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1016\/j.cell.2024.08.021","volume":"187","author":"Y Yang","year":"2024","unstructured":"Yang Y, Lu X, Liu N, Ma S, Zhang H, Zhang Z, et al. Metformin decelerates aging clock in male monkeys. Cell. 2024;187:6358\u201378.e29","journal-title":"Cell"},{"key":"7598_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41418-020-00645-3","volume":"28","author":"J Liang","year":"2021","unstructured":"Liang J, Niu Z, Zhang B, Yu X, Zheng Y, Wang C, et al. p53-dependent elimination of aneuploid mitotic offspring by entosis. Cell Death Differ. 2021;28:799\u2013813","journal-title":"Cell Death Differ"},{"key":"7598_CR44","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/cr.2014.137","volume":"24","author":"Q Sun","year":"2014","unstructured":"Sun Q, Cibas ES, Huang H, Hodgson L, Overholtzer M. Induction of entosis by epithelial cadherin expression. Cell Res. 2014;24:1288\u201398","journal-title":"Cell Res"},{"key":"7598_CR45","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.celrep.2020.108071","volume":"32","author":"M Wang","year":"2020","unstructured":"Wang M, Niu Z, Qin H, Ruan B, Zheng Y, Ning X, et al. Mechanical ring interfaces between adherens junction and contractile actomyosin to coordinate entotic cell-in-cell formation. Cell Rep. 2020;32:108071","journal-title":"Cell Rep"},{"key":"7598_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-017-0677-9","volume":"16","author":"M Yu","year":"2017","unstructured":"Yu M, Xue Y, Zheng J, Liu X, Yu H, Liu L, et al. Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p\/FEZF1\/CDC25A pathway. Mol Cancer. 2017;16:110","journal-title":"Mol Cancer"},{"key":"7598_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1476-4598-7-19","volume":"7","author":"X Yan","year":"2008","unstructured":"Yan X, Chua MS, He J, So SK. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer. 2008;7:19","journal-title":"Mol Cancer"},{"key":"7598_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13046-022-02558-0","volume":"41","author":"X Liu","year":"2022","unstructured":"Liu X, Zheng Y, Xiao M, Chen X, Zhu Y, Xu C, et al. SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis. J Exp Clin Cancer Res. 2022;41:353","journal-title":"J Exp Clin Cancer Res"},{"key":"7598_CR49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00401-011-0934-8","volume":"123","author":"KM Lau","year":"2012","unstructured":"Lau KM, Chan QK, Pang JC, Ma FM, Li KK, Yeung WW, et al. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration\/invasion through a cdc25A-independent pathway in medulloblastoma. Acta Neuropathol. 2012;123:553\u201371","journal-title":"Acta Neuropathol"},{"key":"7598_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biopha.2018.11.010","volume":"110","author":"MS Dorasamy","year":"2019","unstructured":"Dorasamy MS, Ab A, Nellore K, Wong PF. Synergistic inhibition of melanoma xenografts by Brequinar sodium and doxorubicin. Biomed Pharmacother. 2019;110:29\u201336","journal-title":"Biomed Pharmacother"},{"key":"7598_CR51","doi-asserted-by":"publisher","first-page":"e111920","DOI":"10.1371\/journal.pone.0111920","volume":"9","author":"G Jiang","year":"2014","unstructured":"Jiang G, Li RH, Sun C, Liu YQ, Zheng JN. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. PLoS ONE. 2014;9:e111920","journal-title":"PLoS ONE"},{"key":"7598_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158\u201366","journal-title":"J Clin Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07598-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07598-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07598-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:02:03Z","timestamp":1744380123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07598-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7598"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07598-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study does not involve animal or human clinical trials. All the data used in this study are from public databases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"276"}}